4basebio (LON:4BB - Get Free Report)'s stock had its "outperform" rating reiterated by analysts at Royal Bank Of Canada in a research note issued on Thursday,London Stock Exchange reports. They currently have a GBX 1,600 price target on the stock. Royal Bank Of Canada's target price points to a potential upside of 113.19% from the company's previous close.
4basebio Stock Performance
LON 4BB opened at GBX 750.50 on Thursday. The stock has a market cap of £116.21 million, a PE ratio of -798.40 and a beta of 1.09. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. 4basebio has a twelve month low of GBX 704.50 and a twelve month high of GBX 1,500. The stock has a fifty day simple moving average of GBX 877.32 and a 200-day simple moving average of GBX 1,012.76.
4basebio (LON:4BB - Get Free Report) last released its earnings results on Monday, September 29th. The company reported GBX (50) earnings per share for the quarter. Equities analysts anticipate that 4basebio will post -3.43 earnings per share for the current year.
Insider Buying and Selling
In other news, insider Heikki Lanckriet purchased 2,000 shares of the business's stock in a transaction on Monday, September 29th. The shares were bought at an average price of GBX 749 per share, with a total value of £14,980. 12.02% of the stock is currently owned by company insiders.
4basebio Company Profile
(
Get Free Report)
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider 4basebio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4basebio wasn't on the list.
While 4basebio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
